Compare NRXS & BCIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NRXS | BCIC |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance: Consumer Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.9M | 74.1M |
| IPO Year | 2023 | 2006 |
| Metric | NRXS | BCIC |
|---|---|---|
| Price | $4.44 | $5.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $11.00 | $8.50 |
| AVG Volume (30 Days) | ★ 146.5K | 82.0K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | ★ 21.05% |
| EPS Growth | 22.13 | ★ 262.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,569,282.00 | N/A |
| Revenue This Year | $118.53 | N/A |
| Revenue Next Year | $101.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $2.50 | $4.99 |
| 52 Week High | $9.33 | $13.44 |
| Indicator | NRXS | BCIC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
BCP Investment Corp is an externally managed, non-diversified closed-end investment company. The company invests in secured term loans, bonds or notes and mezzanine debt in privately-held middle market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt and selected equity investments in privately-held middle market companies.